Stockreport

Akers Biosciences Acquires Licenses to Coronavirus Vaccine Candidate from Premas Biotech

AKERS BIOSCIENCES INC COMMON S  (AKER) 
US:NASDAQ Investor Relations: akersbio.com/investor-center
PDF Established D-Crypt™ platform will be used to develop a proof-of-concept targeting three of the top five viral vaccine protein candidates for CoronavirusCurrent Regulato [Read more]